Douglas Doerfler - Jan 3, 2023 Form 4 Insider Report for MAXCYTE, INC. (MXCT)

Role
President and CEO, Director
Signature
/s/ Brian F. Leaf, attorney-in-fact
Stock symbol
MXCT
Transactions as of
Jan 3, 2023
Transactions value $
-$151,230
Form type
4
Date filed
1/5/2023, 04:39 PM
Previous filing
Mar 29, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MXCT Common Stock Options Exercise $425 +10.6K +3.19% $0.04* 344K Jan 3, 2023 Direct F1
transaction MXCT Common Stock Sale -$54.4K -10.6K -3.09% $5.13 333K Jan 3, 2023 Direct F1, F2
transaction MXCT Common Stock Options Exercise $366 +9.15K +2.75% $0.04* 342K Jan 4, 2023 Direct F1
transaction MXCT Common Stock Sale -$46.4K -9.15K -2.67% $5.07 333K Jan 4, 2023 Direct F1, F3
transaction MXCT Common Stock Options Exercise $409 +10.2K +3.07% $0.04* 343K Jan 5, 2023 Direct F1
transaction MXCT Common Stock Sale -$51.6K -10.2K -2.98% $5.04 333K Jan 5, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -10.6K -2.38% $0.00 434K Jan 3, 2023 Common Stock 10.6K $0.04 Direct F1, F5
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -9.15K -2.11% $0.00 425K Jan 4, 2023 Common Stock 9.15K $0.04 Direct F1, F5
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -10.2K -2.41% $0.00 415K Jan 5, 2023 Common Stock 10.2K $0.04 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 This option is fully vested and exercisable.